PeerVoice Digestive Diseases Audio

"De-Stigmatising Viral Hepatitis: Overcoming the Impact of the Whispered Epidemics!"

Shining a Light on the Treatment of Primary Hyperoxaluria 1: Does the Evidence Improve Our Options?

Applying Revised Treatment Guidelines for Advanced Hepatocellular Carcinoma: Considerations in Real-Life Practice

Visit https://www.peervoice.com/FKJ860 to view the entire programme with slides. After completing “"The Changing Landscape for SCAC: What Clinicians Need to Know Now"”, participants will be able to: Summarise the latest clinical evidence for managing patients with squamous cell carcinoma of the anal canal (SCAC); Describe the strengths and limitations of these data within the context of current clinical practice; Discuss how these data may be applied to current clinical practice

Visit https://www.peervoice.com/BFC860 to view the entire programme with slides. After completing “Incretin Effect 101: Why We Need to Look Beyond GLP-1 in T2DM”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how this data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM; Recognise the benefits of incretin therapies beyond glycaemic control in patients with T2DM.

Visit https://www.peervoice.com/TFW860 to view the entire programme with slides. After completing “The Cancer No One Wants to Talk About: Squamous Cell Carcinoma of the Anal Canal”, participants will be able to: Recognise the stigma associated with squamous cell carcinoma of the anal canal (SCAC); Describe the typical presentation and treatment of a patient with SCAC; Develop strategies to facilitate talking to patients about SCAC.

Visit https://www.peervoice.com/PUS860 to view the entire programme with slides. After completing “Understanding the Impact of Gene Fusion Detection in NSCLC: The Latest Updates on Testing and Treatment Strategies”, participants will be able to: Explain how adeno-associated virus (AAV)–based gene therapy is revolutionising medicine; Differentiate between in vivo and ex vivo gene therapies; Summarise the key features of a condition/disorder that could make it suitable for an AAV-based gene therapy approach; Discuss the key ethical issues surrounding gene therapy; Describe the differences in the safety profile of non-integrating vs integrating gene therapy vectors; Identify the conditions/disorders where there are ongoing clinical trials with AAV-based gene therapies.

Visit https://www.peervoice.com/YAP860 to view the entire programme with slides. After completing “Non-Oncotic Methods for Managing the Milieu of Decompensated Liver Cirrhosis”, participants will be able to: Describe the non-oncotic properties of human albumin and how they relate to the pathology of decompensated cirrhosis; Define the importance of the dosing and administration regimen for human albumin in patients with decompensated cirrhosis and the evidence that supports this approach; Apply practical strategies to identify those patients who will benefit most from a human albumin plus standard medical therapy (SMT) regimen.

Visit https://www.peervoice.com/AMX860 to view the entire programme with slides. After completing “Acute Psychosis: When to Suspect Acute Hepatic Porphyria”, participants will be able to: Recognise acute hepatic porphyria (AHP) in patients with acute psychosis; Identify patients with psychological symptoms who should be screened for AHP; Describe the importance of a multidisciplinary team approach in the management of patients with AHP.

Visit https://www.peervoice.com/WHZ860 to view the entire programme with slides. After completing “Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed”, participants will be able to: Explain how bowel urgency can impact a patient’s quality of life; Apply practical strategies for identifying and assessing patients with ulcerative colitis who are suffering from bowel urgency; Describe the clinical data for emerging therapies that are being assessed on their impact on bowel urgency.